Company intelligence / Profile preview

Custodix

Sint‑Martens‑Latem, Belgium

Ownership: Private
Development stage: Other

Overview

Custodix did not develop therapeutics; it provided a real‑world data and workflow platform (InSite) used by hospitals, academic centers, pharma and CROs for clinical trial design, feasibility and patient recruitment, and was acquired by TriNetX in 2019 to form part of what is described as the world’s largest clinical research network[3][4][6].

Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Hospitals and healthcare organizations participating in the InSite network across 12 European countries[4][6]Pharmaceutical companies and CROs using InSite/TriNetX for clinical trial design and recruitment (TriNetX industry partners include large pharma such as Novartis, Sanofi and Pfizer, and CROs such as Syneos and ICON, which post‑deal gain access to the InSite network)[4][6]

Beyond the preview

Go deeper on Custodix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Custodix.

Explore the full profile